4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this clinical trial with BI 207127 is to see the effect of 4 week
combination of BI 207127 with Peginterferon alfa (Peg-IFN) and Ribavirin (RBV) on hepatitis C
virus (HCV) virus load and how safe BI 207127 is in this combination in HCV infected
patients.